Integra LifeSciences (NASDAQ:IART) Issues FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 2.300-2.400 for the period, compared to the consensus earnings per share estimate of 2.460. The company issued revenue guidance of $1.6 billion-$1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.550-0.590 EPS.

Integra LifeSciences Trading Down 21.2%

IART opened at $12.68 on Friday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The stock’s 50 day moving average price is $16.69 and its 200-day moving average price is $15.15. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49. The stock has a market cap of $986.12 million, a price-to-earnings ratio of -140.87, a P/E/G ratio of 0.83 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts forecast that Integra LifeSciences will post 2.46 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on IART. UBS Group assumed coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective for the company. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. Citigroup reaffirmed a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Finally, BMO Capital Markets initiated coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and a consensus target price of $18.86.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra expects to generate strong cash flow despite the disruption, while the proposed seven-year, $600 million Senior Secured Term Loan B could improve liquidity and refinance existing obligations. Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
• Neutral Sentiment: Preliminary third-quarter adjusted EPS guidance is $0.55-$0.59, broadly in line with the $0.56 analyst consensus, suggesting the immediate-quarter impact may be manageable. Truist also upgraded the shares to a “Hold,” indicating a more balanced view rather than a bullish recommendation. Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
• Negative Sentiment: Integra reduced its 2026 revenue forecast to $1.634 billion-$1.654 billion from $1.654 billion-$1.695 billion. Full-year EPS guidance was lowered to $2.30-$2.40 from $2.40-$2.50, below the $2.46 consensus estimate. The cuts reflect production interruptions and millions of dollars in costs associated with the Cincinnati flooding. Integra LifeSciences Lowers Revenue and Earnings Outlook for 2026
• Negative Sentiment: The $600 million debt refinancing may support operations, but it also raises concerns about borrowing costs and leverage, particularly as profitability is being reduced by the flood-related disruption. The combination of lower guidance, facility uncertainty and additional secured debt explains why IART shares have decreased sharply and traded at unusually high volume. Integra Lowers FY26 Forecast Following Cincinnati Flood; Plans $600M Debt Refinance

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.